Inclusion diagram. 202 sarcoma patients were included. Overall, 243 pre-treatment multidisciplinary assessments were realized, since some patients received several lines of treatment during the study period. Among them, 157 patients underwent medication reconciliation (MR) by a pharmacist. The pharmacist couldn’t see every patient in pre-therapeutic assessment for practical reasons (unavailability)

Inclusion diagram. 202 sarcoma patients were included. Overall, 243 pre-treatment multidisciplinary assessments were realized, since some patients received several lines of treatment during the study period. Among them, 157 patients underwent medication reconciliation (MR) by a pharmacist. The pharmacist couldn’t see every patient in pre-therapeutic assessment for practical reasons (unavailability)

Source publication
Article
Full-text available
Background The risk of drug–drug interactions (DDI) has become a major issue in cancer patients. However, data in sarcoma patients are scarce. We aimed to evaluate the frequency and the factors associated with DDI with antitumor treatments, and to evaluate the impact of a pharmacist evaluation before anticancer treatment.Patients and methodsWe perf...